These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 12755664)

  • 21. A population-based cost-effectiveness analysis of olanzapine and risperidone among ambulatory patients with schizophrenia.
    Cooper D; Moisan J; Abdous B; Grégoire JP
    Can J Clin Pharmacol; 2008; 15(3):e385-97. PubMed ID: 18953083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model.
    Vera-Llonch M; Delea TE; Richardson E; Rupnow M; Grogg A; Oster G
    Value Health; 2004; 7(5):569-84. PubMed ID: 15367252
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.
    Gibson PJ; Damler R; Jackson EA; Wilder T; Ramsey JL
    Value Health; 2004; 7(1):22-35. PubMed ID: 14720128
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
    Conley RR; Mahmoud R
    Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol.
    Almond S; O'Donnell O
    Pharmacoeconomics; 2000 Apr; 17(4):383-9. PubMed ID: 10947493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of co-morbidities with prescribing patterns and cost savings: olanzapine versus risperidone for schizophrenia.
    Yu W; Ren XS; Lee AF; Herz L; Huang YH; Kazis LE
    Pharmacoeconomics; 2006; 24(12):1233-48. PubMed ID: 17129077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic outcomes associated with olanzapine versus risperidone in the treatment of uncontrolled schizophrenia.
    Zhao Z
    Curr Med Res Opin; 2004 Jul; 20(7):1039-48. PubMed ID: 15265249
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of atypical antipsychotics in a Veterans Affairs hospital.
    Schwartz TL; Saba M; Hardoby W; Virk S; Masand PS
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Oct; 26(6):1207-10. PubMed ID: 12452548
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia.
    Revicki DA
    Schizophr Res; 1999 Mar; 35 Suppl():S101-9. PubMed ID: 10190231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Olanzapine. A pharmacoeconomic review of its use in schizophrenia.
    Foster RH; Goa KL
    Pharmacoeconomics; 1999 Jun; 15(6):611-40. PubMed ID: 10538333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A cost-effectiveness clinical decision analysis model for treatment of Schizophrenia.
    Palmer CS; Brunner E; Ruíz-Flores LG; Paez-Agraz F; Revicki DA
    Arch Med Res; 2002; 33(6):572-80. PubMed ID: 12505105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comments to the editor on "Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model".
    Clewell JD; Baker RW
    Value Health; 2005; 8(2):175-6. PubMed ID: 15804326
    [No Abstract]   [Full Text] [Related]  

  • 33. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
    Rosenheck R; Perlick D; Bingham S; Liu-Mares W; Collins J; Warren S; Leslie D; Allan E; Campbell EC; Caroff S; Corwin J; Davis L; Douyon R; Dunn L; Evans D; Frecska E; Grabowski J; Graeber D; Herz L; Kwon K; Lawson W; Mena F; Sheikh J; Smelson D; Smith-Gamble V;
    JAMA; 2003 Nov; 290(20):2693-702. PubMed ID: 14645311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia.
    Bounthavong M; Okamoto MP
    J Eval Clin Pract; 2007 Jun; 13(3):453-60. PubMed ID: 17518814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Service use and costs of treating schizophrenia with atypical antipsychotics.
    Lewis M; McCrone P; Frangou S
    J Clin Psychiatry; 2001 Oct; 62(10):749-56. PubMed ID: 11816863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comments on cost analysis of risperidone versus olanzapine.
    Duggal HS; Gandotra G
    J Clin Psychiatry; 2004 Jun; 65(6):879-80; author reply 880. PubMed ID: 15291670
    [No Abstract]   [Full Text] [Related]  

  • 37. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine.
    Kinon BJ; Basson BR; Gilmore JA; Malcolm S; Stauffer VL
    J Clin Psychiatry; 2000 Nov; 61(11):833-40. PubMed ID: 11105736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.
    Edwards NC; Locklear JC; Rupnow MF; Diamond RJ
    Pharmacoeconomics; 2005; 23 Suppl 1():75-89. PubMed ID: 16416763
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia.
    Barnett PG; Scott JY; Krystal JH; Rosenheck RA;
    J Clin Psychiatry; 2012 May; 73(5):696-702. PubMed ID: 22697193
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inpatient length of stay and atypical antipsychotic use among elderly patients with psychiatric disorders and Alzheimer's disease.
    Edell WS; Rupnow MF
    Manag Care Interface; 2003 May; 16(5):64-7. PubMed ID: 12789866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.